Update on Novel Drugs for Primary Care Practice: Drugs Approved by the U.S. Food and Drug Administration in 2015
Authors: Gerald W. Smetana
Journal: Annals of Internal Medicine (2016)

Updates3 May 2016Update on Novel Drugs for Primary Care Practice: Drugs Approved by the U.S. Food and Drug Administration in 2015Gerald W. Smetana, MDGerald W. Smetana, MDFrom Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-3104 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It is challenging for internists to keep up with the large number of new drugs that are approved by the U.S. Food and Drug Administration (FDA) each year. Much of the new research appears in journals not commonly read by internists. In 2015, the FDA approved 45 new drugs: 22 drugs for use primarily by subspecialists, 7 “me too” drugs, 7 biologics not relevant to primary care, and 9 drugs that were both novel and potentially relevant for general internal medicine practice. Among these 9 novel drugs are several newly approved biologic therapies that have the potential for use in ...References1. U.S. Food and Drug Administration. Novel drug approvals for 2015. Accessed at www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm on 12 December 2015. Google Scholar2. U.S. Centers for Disease Control and Prevention. High cholesterol facts. 17 March 2015. Accessed at www.cdc.gov/cholesterol/facts.htm on 28 December 2015. Google Scholar3. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99. [PMID: 25773378] doi:10.1056/NEJMoa1501031 CrossrefMedlineGoogle Scholar4. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. FDA Advisory Committee Briefing Document Praluent (alirocumab). Briefing document. BLA 125559. Praluent (alirocumab) injection. 9 June 2015. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449867.pdf on 27 February 2016. Google Scholar5. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51. [PMID: 25915661]. doi:10.7326/M14-2957 LinkGoogle Scholar6. Dunne Roberts M. Alirocumab. BLA 125559. Clinical safety review. Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research. 9 June 2015. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM452345.pdf on 27 February 2016. Google Scholar7. Burness CB. Idarucizumab: first global approval. Drugs. 2015;75:2155-61. [PMID: 26578027] doi:10.1007/s40265-015-0508-5 CrossrefMedlineGoogle Scholar8. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680-90. [PMID: 26088268] doi:10.1016/S0140-6736(15)60732-2 CrossrefMedlineGoogle Scholar9. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-20. [PMID: 26095746] doi:10.1056/NEJMoa1502000 CrossrefMedlineGoogle Scholar10. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943-51. [PMID: 25789661] doi:10.1160/TH14-12-1080 CrossrefMedlineGoogle Scholar11. Boehringer Ingelheim Pharmaceuticals. Praxbind (idarucizumab) injection, for intravenous use. Prescribing information. October 2015. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf on 27 February 2016. Google Scholar12. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413-24. [PMID: 26559317] doi:10.1056/NEJMoa1510991 CrossrefMedlineGoogle Scholar13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35. [PMID: 2883575] CrossrefMedlineGoogle Scholar14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302. [PMID: 2057034] CrossrefMedlineGoogle Scholar15. Pereira-Barretto AC. Cardiac and hemodynamic benefits: mode of action of ivabradine in heart failure. Adv Ther. 2015;32:906-19. [PMID: 26521191] doi:10.1007/s12325-015-0257-6 CrossrefMedlineGoogle Scholar16. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16. [PMID: 18757088] doi:10.1016/S0140-6736(08)61170-8. CrossrefMedlineGoogle Scholar17. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-85. [PMID: 20801500] doi:10.1016/S0140-6736(10)61198-1 CrossrefMedlineGoogle Scholar18. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091-9. [PMID: 25176136] doi:10.1056/NEJMoa1406430 CrossrefMedlineGoogle Scholar19. Ivabradine (Corlanor) for heart failure. Med Lett Drugs Ther. 2015;57:75-6. [PMID: 25989196] MedlineGoogle Scholar20. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-41. [PMID: 21800283] doi:10.1002/art.30520 CrossrefMedlineGoogle Scholar21. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431-46. [PMID: 23024028] doi:10.1002/acr.21772 CrossrefMedlineGoogle Scholar22. U.S. Food and Drug Administration. Arthritis Advisory Committee meeting. NDA 207988: lesinurad for the proposed indication of treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor. 23 October 2015. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM467942.pdf on 27 February 2016. Google Scholar23. Ardea Biosciences. Lesinurad in combination with a xanthine oxidase inhibitor for treatment of hyperuricemia associated with gout. Briefing document for the Arthritis Advisory Committee of the FDA. 23 October 2015. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM467951.pdf on 27 February 2016. Google Scholar24. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. [PMID: 24523597] MedlineGoogle Scholar25. Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145:329-38 e1. [PMID: 23583433] doi:10.1053/j.gastro.2013.04.006 CrossrefMedlineGoogle Scholar26. Muldowney L. New drug application, medical review. Eluxadoline (JNJ-27018966). New drug application (NDA) 206940. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. 26 June 2014. Accessed at www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf on 27 February 2016. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.Disclosures: The author has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-3104.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.Corresponding Author: Gerald W. Smetana, MD, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, YA-102C, 330 Brookline Avenue, Boston, MA 02215; e-mail, [email protected]harvard.edu.Author Contributions: Conception and design: G.W. Smetana.Analysis and interpretation of the data: G.W. Smetana.Drafting of the article: G.W. Smetana.Final approval of the article: G.W. Smetana.Collection and assembly of data: G.W. Smetana. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTrends in FDA drug approvals over last 2 decades: An observational study 3 May 2016Volume 164, Issue 9Page: W48-W54KeywordsCholesterolDrugsFood and Drug AdministrationHeart failureHemorrhageLow density lipoproteinMortalitySafetyThrombinUric acid ePublished: 3 May 2016 Issue Published: 3 May 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...